These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
250 related items for PubMed ID: 10834864
1. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Mok MY, Farewell VT, Isenberg DA. Ann Rheum Dis; 2000 Jun; 59(6):462-7. PubMed ID: 10834864 [Abstract] [Full Text] [Related]
2. Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus. Woo KS, Kim KE, Kim JM, Han JY, Chung WT, Kim KH. Korean J Lab Med; 2010 Feb; 30(1):38-44. PubMed ID: 20197721 [Abstract] [Full Text] [Related]
5. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus. İlgen U, Yayla ME, Ateş A, Okatan İE, Yurteri EU, Torgutalp M, Keleşoğlu ABD, Turgay TM, Kınıklı G. Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535 [Abstract] [Full Text] [Related]
7. Prevalence of antiphospholipid antibodies in patients with overt myocardial dysfunction in systemic lupus erythematosus. A case-control study. Gawalkar AA, Bahl A, Ahluwalia J, Sood A, Sharma A, Sharma S, Dhir V. Lupus; 2020 Oct; 29(12):1503-1508. PubMed ID: 32752919 [Abstract] [Full Text] [Related]
9. BF*F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus. Picceli VF, Skare TL, Nisihara RM, Nass FR, Messias-Reason IT, Utiyama SR. Lupus; 2016 Apr; 25(4):412-7. PubMed ID: 26537423 [Abstract] [Full Text] [Related]
11. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Perez-Villa F, Font J, Azqueta M, Espinosa G, Pare C, Cervera R, Reverter JC, Ingelmo M, Sanz G. Arthritis Rheum; 2005 Jun 15; 53(3):460-7. PubMed ID: 15934103 [Abstract] [Full Text] [Related]
12. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ghirardello A, Doria A, Ruffatti A, Rigoli AM, Vesco P, Calligaro A, Gambari PF. Ann Rheum Dis; 1994 Feb 15; 53(2):140-2. PubMed ID: 8129460 [Abstract] [Full Text] [Related]
13. Non-corticosteroid risk factors of symptomatic avascular necrosis of bone in systemic lupus erythematosus: A retrospective case-control study. Faezi ST, Hoseinian AS, Paragomi P, Akbarian M, Esfahanian F, Gharibdoost F, Akhlaghi M, Nadji A, Jamshidi AR, Shahram F, Nejadhosseinian M, Davatchi F. Mod Rheumatol; 2015 Jul 15; 25(4):590-4. PubMed ID: 25528860 [Abstract] [Full Text] [Related]
14. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. López-Soto A, Cervera R, Font J, Bové A, Reverter JC, Muñoz FJ, Miret C, Espinosa G, Ordinas A, Ingelmo M. Clin Exp Rheumatol; 1997 Jul 15; 15(2):143-9. PubMed ID: 9196865 [Abstract] [Full Text] [Related]
16. Predictors of avascular necrosis of the hip in Emiratis patients with systemic lupus erythematosus. Al Saleh J, El Sayed M, Salah N, Harb D, Khan N, Mohammed N. Egypt J Immunol; 2010 Jul 15; 17(1):29-40. PubMed ID: 22053607 [Abstract] [Full Text] [Related]